首页> 外文OA文献 >Reproducibility and prognostic value of WHO1973 and WHO2004 grading systems in TaT1 urothelial carcinoma of the urinary bladder
【2h】

Reproducibility and prognostic value of WHO1973 and WHO2004 grading systems in TaT1 urothelial carcinoma of the urinary bladder

机译:WHO1973和WHO2004分级系统在膀胱TaT1尿路上皮癌中的重复性和预后价值

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Background: European treatment guidelines of TaT1 urinary bladder urothelial carcinomas depend highly on stage and WHO1973-grade but grading reproducibility is wanting. The newer WHO2004 grading system is still debated and both systems are currently used.Aims: To compare reproducibility and prognostic value (of stage progression) of the WHO1973 and WHO2004.Methods: One hundred and ninety-three primary urothelial carcinomas were reviewed. Follow-up data were retrieved from the patient records. Kappa statistics and Harrell's C-index were used.Results: Median follow-up was 75 months (range 1–127). 17 patients (9%) progressed, 82% of these within and 18% after 60 months. The distribution of WHO73-grades 1, 2 and 3 was 23%, 51% and 26%, interobserver agreement for each individual grade was 66% (kappa = 0.68), while for grades 1&2 versus 3 89% (kappa = 0.68). Intraobserver reproducibility was 68–63% for WHO73 and 88–89% for WHO73 as 1&2 vs.3. Progression free survival rates at 5 years were 95% (grade 1), 98% (grade 2) and 82% (grade 3) and 96% and 82% for grades 1&2 versus 3 (Hazard Ratio, HR, 5.4, p = 0.003). Using WHO2004, 62% were low grade and 38% high grade, inter-observer agreement 87% (kappa = 0.70), intraobserver reproducibility 93%, and progression free 5-year survival rates 97% and 85% (HR 6.6, p = 0.004). Positive and negative predictive values for stage progression within 5 years for the WHO73 (1&2 vs. 3) were 18% and 96%, and 15% and 97% for the WHO04. Using Harrell's C-index, none of the grading systems was prognostically superior.Conclusion: None of the grading systems is prognostically stronger than the others. Most importantly, inter-observer reproducibility and sensitivities for stage progression of both systems are low and need improvement for optimal treatment.
机译:背景:TaT1膀胱尿路上皮癌的欧洲治疗指南高度依赖于分期和WHO1973级,但需要分级可重复性。目的:比较WHO1973和WHO2004的可重复性和预后价值(阶段进展)。方法:审查了193例原发性尿路上皮癌。从患者记录中获取随访数据。结果:中位随访时间为75个月(范围1–127)。 17例(9%)进展,其中82%在60个月内进展,18%在60个月后进展。 WHO73等级1、2和3的分布分别为23%,51%和26%,每个个体等级之间的观察员之间的一致性为66%(kappa = 0.68),而等级1&2与3%的3 89%(kappa = 0.68)。 1和2与3相比,WHO73的观察者内可重复性为68-63%,WHO73的88-89%。 5年无进展生存率分别为95%(1级),98%(2级)和82%(3级),分别为1&2和3与3级(危险比,HR,5.4,p = 0.003)分别为96%和82% )。使用WHO2004,低级和高等级分别为62%,观察员间一致性87%(kappa = 0.70),观察员内可重复性93%和无进展5年生存率97%和85%(HR 6.6,p = 0.004)。 WHO73(1&2 vs. 3)在5年内分期进展的阳性和阴性预测值分别为18%和96%,WHO04为15%和97%。使用Harrell的C指数,没有一个评分系统在预后方面是优越的。结论:在评分上,没有一个评分系统比其他系统强。最重要的是,对于两个系统的阶段进展,观察者之间的可重复性和敏感性均很低,需要改进以进行最佳治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号